Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1990-10-11
|
pubmed:abstractText |
61 patients with small cell lung cancer in a poor prognosis group were treated with chemotherapy and with thoracic radiotherapy if they had 'limited stage' disease. No prophylactic cranial irradiation was given. Chemotherapy comprised doxorubicin 50 mg/m2 and ifosfamide 5 g/m2 with mesna on day 1, and etoposide 120 mg/m2 intravenously on days 1 and 2 and 240 mg/m2 orally on day 3. Treatment was repeated every 3 weeks for a maximum of six courses and no dosage reductions were allowed. Complete response rate in limited stage patients was 55% and 16% in extensive stage patients. The partial responses were 38% and 66% respectively. Overall median survival was 10.5 months with 2-year survival of 14%. The corresponding values for limited stage disease were 13 months and 16% and for extensive stage disease 8 months and 13%. Despite the addition of doxorubicin at a somewhat higher dosage than usual in this type of regimen and a policy of no dose reduction, toxicity was generally mild. There was, however, a 19% relapse rate in complete responders in the brain, apparently as the sole site of disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
691-4
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:2168191-Adult,
pubmed-meshheading:2168191-Aged,
pubmed-meshheading:2168191-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2168191-Carcinoma, Small Cell,
pubmed-meshheading:2168191-Doxorubicin,
pubmed-meshheading:2168191-Etoposide,
pubmed-meshheading:2168191-Female,
pubmed-meshheading:2168191-Humans,
pubmed-meshheading:2168191-Ifosfamide,
pubmed-meshheading:2168191-Lung Neoplasms,
pubmed-meshheading:2168191-Male,
pubmed-meshheading:2168191-Middle Aged,
pubmed-meshheading:2168191-Prognosis
|
pubmed:year |
1990
|
pubmed:articleTitle |
Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
|
pubmed:affiliation |
Department of Medical Oncology, Christie Hospital, Manchester, U.K.
|
pubmed:publicationType |
Journal Article
|